Regulation of invadopodia formation and activity by CD147

被引:43
作者
Grass, G. Daniel [1 ]
Bratoeva, Momka [1 ]
Toole, Bryan P. [1 ]
机构
[1] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA
基金
美国国家卫生研究院;
关键词
CD147; Invadopodia; MT1-MMP (MMP14); Invasion; Breast cancer; MATRIX-METALLOPROTEINASE INDUCER; NF-KAPPA-B; MONOCARBOXYLATE TRANSPORTERS; EMMPRIN EXPRESSION; MMP-2; PRODUCTION; CANCER-CELLS; TUMOR-CELLS; BASIGIN; COLLAGENASE; HYALURONAN;
D O I
10.1242/jcs.097956
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A defining feature of malignant tumor progression is cellular penetration through the basement membrane and interstitial matrices that separate various cellular compartments. Accumulating evidence supports the notion that invasive cells employ specialized structures termed invadopodia to breach these structural barriers. Invadopodia are actin-based, lipid-raft-enriched membrane protrusions containing membrane-type-1 matrix metalloproteinase (MT1-MMP; also known as matrix metalloproteinase 14; MMP14) and several signaling proteins. CD 147 (emmprin, basigin), an immunoglobulin superfamily protein that is associated with tumor invasion and metastasis, induces the synthesis of various matrix metalloproteinases in many systems. In this study we show that upregulation of CD 147 is sufficient to induce MT1-MMP expression, invasiveness and formation of invadopodia-like structures in non-transformed, non-invasive, breast epithelial cells. We also demonstrate that CD 147 and MT1-MMP are in close proximity within these invadopodia-like structures and co-fractionate in membrane compartments with the properties of lipid rafts. Moreover, manipulation of CD147 levels in invasive breast carcinoma cells causes corresponding changes in MT1-MMP expression, invasiveness and invadopodia formation and activity. These findings indicate that CD 147 regulates invadopodia formation and activity, probably through assembly of MT1-MMP-containing complexes within lipid-raft domains of the invadopodia.
引用
收藏
页码:777 / 788
页数:12
相关论文
共 62 条
[1]   Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains [J].
Annabi, B ;
Lachambre, MP ;
Bousquet-Gagnon, N ;
Pagé, M ;
Gingras, D ;
Béliveau, R .
BIOCHEMICAL JOURNAL, 2001, 353 :547-553
[2]  
Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15
[3]   Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function [J].
Artym, VV ;
Zhang, Y ;
Seillier-Moiseiwitsch, FO ;
Yamada, KM ;
Mueller, SC .
CANCER RESEARCH, 2006, 66 (06) :3034-3043
[4]   Basigin-2 is a cell surface receptor for soluble basigin ligand [J].
Belton, Robert J., Jr. ;
Chen, Li ;
Mesquita, Fernando S. ;
Nowak, Romana A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (26) :17805-17814
[5]   Generation of monoclonal antibodies to integrin-associated proteins - Evidence that alpha(3)beta(1) complexes with EMMPRIN/basigin/OX47/M6 [J].
Berditchevski, F ;
Chang, S ;
Bodorova, J ;
Hemler, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (46) :29174-29180
[6]  
BISWAS C, 1995, CANCER RES, V55, P434
[7]   EMMPRIN-mediated MMP regulation in tumor and endothelial cells [J].
Caudroy, S ;
Polette, M ;
Nawrocki-Raby, B ;
Cao, J ;
Toole, BP ;
Zucker, S ;
Birembaut, P .
CLINICAL & EXPERIMENTAL METASTASIS, 2002, 19 (08) :697-702
[8]   Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia [J].
Clark, Emily S. ;
Whigham, Amy S. ;
Yarbrough, Wendell G. ;
Weaver, Alissa M. .
CANCER RESEARCH, 2007, 67 (09) :4227-4235
[9]   Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture [J].
Curtin, KD ;
Meinertzhagen, IA ;
Wyman, RJ .
JOURNAL OF CELL SCIENCE, 2005, 118 (12) :2649-2660
[10]   Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: A novel model for tumor progression [J].
Davidson, B ;
Konstantinovsky, S ;
Nielsen, S ;
Dong, HP ;
Berner, A ;
Vyberg, M ;
Reich, R .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7335-7346